Meeting
2021 ASCO Annual Meeting
Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Authors
Scott Kopetz
MD Anderson Cancer Center, Houston, TX
Scott Kopetz , Dan Aderka , Axel Grothey , Eric Van Cutsem , Rona Yaeger , Harpreet Singh Wasan , Takayuki Yoshino , Jayesh Desai , Fortunato Ciardiello , Ashwin Gollerkeri , Adele Golden , Michelle L. Edwards , Josep Tabernero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02928224
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3583)
DOI
10.1200/JCO.2021.39.15_suppl.3583
Abstract #
3583
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.
First Author: Akihito Tsuji
Poster
2014 ASCO Annual Meeting
Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.
First Author: Dominik Paul Modest
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).
First Author: Karam Ashouri